Wu Jiajin, Wei Yuang, Miao Chenkui, Wang Songbo, Wang Xiaoyi, Wang Zengjun
Department of Urology, The First Affiliated Hospital of Nanjing Medical University/Jiangsu Province Hospital, No. 300 Guangzhou Road, Nanjing 210029, China.
Core Facility Center, The First Affiliated Hospital of Nanjing Medical University/Jiangsu Province Hospital, No. 300 Guangzhou Road, Nanjing 210029, China.
J Oncol. 2022 Apr 23;2022:9411692. doi: 10.1155/2022/9411692. eCollection 2022.
mA RNA modification is a common abundant posttranscriptional modification of mRNAs occurring in cancer growth and progression. Accumulated evidence has proved that HNRNPC, which acts as a mA reader, plays an essential role in the promotion of cancer occurrence and development; nevertheless, the role of HNRNPC in papillary renal cell carcinoma remained to be discovered. In this study, we comprehensively identified HNRNPC as a hub gene involved in mA modification in pRCC. Then, the expression level, survival outcomes, PPI network, function enrichment, immune cell infiltration, and single-cell analysis were performed. Finally, we found that HNRNPC significantly promoted renal cell carcinoma proliferation and migration in vitro. In conclusion, our work proved that HNRNPC may act as a momentous mA regulator, as well as a potential targetable biomarker for pRCC.
m⁶A RNA修饰是一种常见且丰富的mRNA转录后修饰，发生于癌症生长和进展过程中。越来越多的证据表明，作为m⁶A阅读蛋白的HNRNPC在促进癌症发生和发展中起着至关重要的作用；然而，HNRNPC在乳头状肾细胞癌中的作用仍有待发现。在本研究中，我们全面鉴定出HNRNPC是参与乳头状肾细胞癌m⁶A修饰的枢纽基因。然后，我们进行了表达水平、生存结果、蛋白质-蛋白质相互作用网络、功能富集、免疫细胞浸润和单细胞分析。最后，我们发现HNRNPC在体外显著促进肾细胞癌的增殖和迁移。总之，我们的研究证明HNRNPC可能是一个重要的m⁶A调节剂，也是乳头状肾细胞癌潜在的可靶向生物标志物。
